Abstract
Keverprazan hydrochloride (凯普拉生) is a potassium ion competitive acid blocker that is being developed by Jiangsu Carephar Pharmaceuticals for the treatment of acid-related disease. Keverprazan hydrochloride was recently approved in China for the treatment of adults with reflux oesophagitis or duodenal ulcer. This article summarizes the milestones in the development of keverprazan hydrochloride leading to this first approval for reflux oesophagitis and duodenal ulcer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Chen S, Liu D, Chen H, et al. The efficacy and safety of keverprazan, a novel potassium-competitive acid blocker, in treating erosive oesophagitis: a phase III, randomised, double-blind multicentre study. Aliment Pharmacol Ther. 2022;55(12):1524–33.
Tan ND, Liu XW, Liu CX, et al. Efficacy of keverprazan for duodenal ulcer: a phase II randomized, double-blind, parallel-controlled trial. J Gastroenterol Hepatol. 2022;37(11):2060–6.
National Medical Products Administration. The State Food and Drug Administration approved the marketing of Caprasen hydrochloride tablets. 15 Feb 2023. https://www.nmpa.gov.cn.
Jiangsu Carephar Pharmaceutical. Keverprazan hydrochloride tablets: Chinese prescribing information [Chinese]. 2023. https://www.nmpa.gov.cn. Accessed 21 Mar 2023.
Fosun Pharma USA. Fosun Pharma and Carephar enter into a global collaboration to co-develop and exclusively commercialize China's first self-developed P-CAB product keverprazan hydrochloride. 19 Sep 2022. http://www.fosunpharma.com.
Li CY, Su M, Yan YY, et al. KFP-H008 blocks gastric acid secretion through inhibiting H(+)-K(+)-ATPase. Eur J Pharmacol. 2017;810:112–9.
Tan N, Miao X, Liao A, et al. The efficacy and safety of keverprazan (H008) in the treatment of duodenal ulcer: a multicentred, randomized, double-blind, active-control trial in China (abstract no. P0098). In: 30th United European Gastroenterology Week 2022.
Funding
The preparation of this review was not supported by any external funding.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Authorship and Conflict of Interest
During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Connie Kang is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.
Ethics approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability
Not applicable.
Additional information
This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Kang, C. Keverprazan Hydrochloride: First Approval. Drugs 83, 639–643 (2023). https://doi.org/10.1007/s40265-023-01865-w
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40265-023-01865-w